» Articles » PMID: 36826025

Loss of Nf1 and Ink4a/Arf Are Associated with Sex-Dependent Growth Differences in a Mouse Model of Embryonal Rhabdomyosarcoma

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2023 Feb 24
PMID 36826025
Authors
Affiliations
Soon will be listed here.
Abstract

Rhabdomyosarcoma (RMS) is an aggressive form of cancer that accounts for half of all pediatric soft tissue sarcomas. Little progress has been made in improving survival outcomes over the past three decades. Mouse models of rhabdomyosarcoma are a critical component of translational research aimed at understanding tumor biology and developing new, improved therapies. Though several models exist, many common mutations found in human rhabdomyosarcoma tumors remain unmodeled and understudied. This study describes a new model of embryonal rhabdomyosarcoma driven by the loss of Nf1 and Ink4a/Arf, two mutations commonly found in patient tumors. We find that this new model is histologically similar to other previously-published rhabdomyosarcoma models, although it substantially differs in the time required for tumor onset and in tumor growth kinetics. We also observe unique sex-dependent phenotypes in both primary and newly-developed orthotopic syngeneic allograft tumors that are not present in previous models. Using in vitro and in vivo studies, we examined the response to vincristine, a component of the standard-of-care chemotherapy for RMS. The findings from this study provide valuable insight into a new mouse model of rhabdomyosarcoma that addresses an ongoing need for patient-relevant animal models to further translational research.

Citing Articles

Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside.

Martynov I, Dhaka L, Wilke B, Hoyer P, Vahdad M, Seitz G Front Oncol. 2024; 14:1333129.

PMID: 38371622 PMC: 10869630. DOI: 10.3389/fonc.2024.1333129.


Molecules at Play in Cancer.

Iacobas D Curr Issues Mol Biol. 2023; 45(3):2182-2185.

PMID: 36975510 PMC: 10047071. DOI: 10.3390/cimb45030140.

References
1.
Hingorani P, Missiaglia E, Shipley J, Anderson J, Triche T, Delorenzi M . Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2015; 21(20):4733-9. PMC: 4610152. DOI: 10.1158/1078-0432.CCR-14-3326. View

2.
Nakahata K, Simons B, Pozzo E, Shuck R, Kurenbekova L, Prudowsky Z . K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. Dis Model Mech. 2022; 15(2). PMC: 8844455. DOI: 10.1242/dmm.049004. View

3.
Ghilu S, Morton C, Vaseva A, Zheng S, Kurmasheva R, Houghton P . Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. Cancer Drug Resist. 2022; 5:80-89. PMC: 8992598. DOI: 10.20517/cdr.2021.112. View

4.
Punyko J, Mertens A, Baker K, Ness K, Robison L, Gurney J . Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer. 2005; 103(7):1475-83. DOI: 10.1002/cncr.20929. View

5.
Comiskey Jr D, Jacob A, Sanford B, Montes M, Goodwin A, Steiner H . A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo. Oncogene. 2017; 37(1):95-106. PMC: 5756115. DOI: 10.1038/onc.2017.282. View